BioSpace News Archive

Grant extends SRI’s long history of collaborations with the National Institutes of Health

Castellum, Inc.’s (OTC:ONOV) President and CEO Mark Fuller provides the following update to the Company’s shareholders: “We are now beginning the second year of our business plan to build a large listed company in the cyber security, information technology, information warfare, and electronic warfare and engineering services space. Good strides have been made in pursuit of our goals and overall plan. A very strong advisory board has been e

Gritstone Oncology, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight multiple cancer types, today reported financial results for the second quarter ended June 30, 2020 and reviewed business highlights. “We have made important advances in our two cancer immunotherapy programs, GRANITE and SLATE, demonstrating early signals of clinical benefit together with a well-

Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced that Amit Rakhit, M.D., MBA, President and Chief Medical Officer, will participate in a panel discussion at the William Blair Biotech Focus Conference 2020. The panel is titled, “New Therapies Impacting the Epilepsy Treatment Landscape,” and will be held on Thursday, A

Catalyst Clinical Research announced today that it has merged with Ce3, Inc . to expand its depth of oncology-specific therapeutic expertise. The combined company is strongly positioned to deliver oncology clinical development services to the biotechnology industry, as Ce3 has provided such services for more than 15 years. Catalys

ArcherDX, Inc. today announced that Jason Myers , Ph.D., Chief Executive Officer and co-founder of ArcherDX, will participate in a fireside chat at the UBS Genomics 2.0 and Medtech Innovations Virtual Summit.

Adaptive Phage Therapeutics (APT), a clinical-stage biotechnology company founded to provide an effective therapeutic response to the global rise of multi-drug resistant (MDR) pathogenic bacteria, today announced Mayo Clinic has committed $1.75M as a lead investor in a $7 million convertible note financing round.

PharmaCyte Biotech, Inc. (OTCQB: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box ® , announced today that the Drug Master File (DMF) that its partner, Austrianova, filed with the U.S. Food and Drug Administration (FDA) has been accepted without any questions or suggested changes. The FDA’s Center

Rafarma Pharmaceuticals, Inc. OTC:(RAFA) presents the following letter to Rafarma shareholders from CEO Vladimir Dolgolenko: To Our Shareholders: During these exciting times I wanted to reach out to our shareholders and clarify some questions I have received. As recently announced, there will be a change in control forthcoming for Rafarma. The change in control will not affect the current share structure of the company. There has bee

Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that its Chief Financial Officer, Joseph J. Ferra, will present a corporate overview at the 2020 Wedbush PacGrow Healthcare Virtual Conference. Details are as follows: 2020 Wedbush PacGrow Healthcare Virtual Conference: Date: Wednesday, August 12 Time: 8:00 a.m. ET A live web